sponsored
PatientsVille.com Logo

PatientsVille

Morphine Sulfate Cr Tablet 10 Mg Medical Research Studies

Up-to-date List of Morphine Sulfate Cr Tablet 10 Mg Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Morphine Sulfate Cr Tablet 10 Mg Medical Research Studies

Rank Status Study
1 Recruiting Heart Failure Management Program Versus Usual Care
Conditions: Cardiac Failure;   Congestive Heart Failure
Interventions: Other: Heart Failure Disease Management Program;   Other: Heart Failure Usual Care
Outcome Measures: 30 day post SNF admission outcomes;   Health status and self care 60 days post SNF admission;   Patients living at home 60 days post-SNF admission with Heart Failure (HF);   Cost-effectiveness
2 Recruiting Caregiver Enhanced Assistance and Support for the Elderly Heart Failure Patient at Hospital Discharge (CEASE-HF)
Condition: Heart Failure
Interventions: Other: Standardized Heart Failure Discharge Summary to Primary Care Physicians©;   Behavioral: Standardized education sessions;   Other: Heart Failure Diuretic Decision Support Tool for Patient Self Management©;   Other: Digital talking scale;   Other: Usual care
Outcome Measures: Patient self care;   Death;   Heart failure readmission;   Emergency room heart failure visits;   Perceived caregiver burden;   Heart failure knowledge acquisition;   Medication adherence;   Referral to heart failure clinic or to long-term care;   Health beliefs;   Depression
3 Recruiting Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Conditions: Heart Failure, Systolic;   Depression;   Cardiovascular Disease
Interventions: Behavioral: Collaborative Care for Heart Failure;   Behavioral: Collaborative Care for Depression
Outcome Measures: Medical Outcomes Study (MOS) 12-Item Short Form Health Survey Mental Component Summary (SF-12 MCS);   Kansas City Cardiomyopathy Questionnaire (KCCQ-12);   Hamilton Rating Scale for Depression (17-Item);   Incidence of Rehospitalization;   Mortality;   Health Care Costs;   Employment
4 Recruiting Palliative Care in Heart Failure
Conditions: Heart Failure;   Heart Diseases;   Cardiovascular Diseases
Intervention: Behavioral: Usual heart failure care + interdisciplinary palliative care
Outcome Measures: Is there an impact on quality of life with the addition of a palliative care intervention?;   Is there an impact on depression and anxiety with the addition of a palliative care intervention?;   Is there an impact on caregiver satisfaction and perception of subject quality of life with the addition of a palliative care intervention?;   Is there an impact on spiritual well-being with the addition of a palliative care intervention?;   Is there an impact on cost and resource utilization with the addition of a palliative care intervention?
5 Recruiting A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Conditions: Heart Failure;   Coronary Artery Disease
Interventions: Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Outcome Measures: Time to the first occurrence of any of the following: death from any cause, myocardial infarction, or stroke;   Time to the first occurrence of either fatal bleeding or bleeding into a critical space with potential for permanent disability;   Time to the first occurrence of either death due to a cardiovascular cause or re-hospitalization for worsening of heart failure;   Time to death due to a cardiovascular cause;   Time to rehospitalization for worsening of heart failure;   Time to rehospitalization for cardiovascular events;   Bleeding requiring hospitalization
6 Recruiting Gas Exchange for Predicting Hospital Heart Failure Readmissions
Condition: Acute Decompensated Heart Failure
Intervention:
Outcome Measures: 1. To evaluate if exercise gas exchange tests can predict 30 day hospital readmission for heart failure.;   2. To evaluate which gas exchange patterns were most highly associated with 30 day risk of readmission for recurrent acute decompensated heart failure.;   3. To determine the incidence of Adverse Events (AE) and Serious Adverse Events (SAE).;   1. To evaluate if exercise gas exchange tests can predict 180 day hospital readmission for heart failure.;   2. To evaluate which gas exchange patterns were most highly associated with 180 day risk of readmission for recurrent acute decompensated heart failure.
7 Unknown  Study of Electrical Bioimpedance in Heart Failure.
Conditions: Heart Failure;   Dyspnea
Intervention: Other: No intervention
Outcome Measures: To identify if electrical bioimpedance analysis is useful for diagnosis, monitoring and prognosis in patients with heart failure.;   To analyze segmental and whole-body bioimpedance measures in a population of heart failure patients with multi frequency body composition analysis;   To study the relation between electrical bioimpedance changes with patients' clinical situation (compensated versus decompensated HF);   To assess potential correlations between impedance, clinical status, heart failure functional class, and NT-proBNP.
8 Recruiting Multicenter Study of Family Nursing to Treat Heart Failure
Condition: Heart Failure
Intervention: Behavioral: Family Focused Nursing
Outcome Measures: Change in Health Related Quality of Life assessed by ≥6 point in Kansas City Cardiomyopathy Questionnaire summary score;   Change in European Heart Failure Self-Care Behavior Scale;   Change in Family Functioning, Health and Social Support scale;   Change in Self-Efficacy for Managing Chronic Disease 6-item scale;   Change in Major Depression Inventory diagnostic scale;   Time for the emergence of total re-admission and re-admission for heart failure;   Time for the emergence of mortality
9 Unknown  Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure
Condition: Heart Failure
Intervention: Other: Surgery
Outcome Measures: Paracrine properties of bone marrow cells from patients with heart failure;   To study preconditioning of different bone marrow stem cells with different cytokines;   To study in detail the temporal and spatial expression of paracrine factors in bone marrow stem cells in vitro, and to study the differences between bone marrow stem cells from patients with and without chronic heart failure;   To evaluate potential molecular mechanisms involved;   To find mechanisms to enhance expansion of different bone marrow stem cells in vitro
10 Not yet recruiting SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
Condition: Heart Failure (HF)
Intervention:
Outcome Measures: Number of heart failure patients with sleep disordered breathing (apnea hypopnoea index >5);   Number of heart failure patients with sleep disordered breathing (apnea hypopnea index >5) when exposed to sleep disordered breathing treatment;   Number of heart failure patients with sleep disordered breathing (apnea hypopnea index >5) when exposed to Heart Failure treatment;   Number of patients adherent to sleep disordered breathing treatment as measured by device reported usage hours;   Number of deaths of patients with HF and sleep disordered breathing (apnea hypopnoea index >5) who are treated for sleep disordered breathing
11 Unknown  Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System
Condition: Heart Failure
Interventions: Device: "Pneumedicare"s monitoring system.;   Device: "Pneumedicare"s monitoring system
Outcome Measure: earliest non-invasive signs for lung congestion and deterioration in the heart failure
12 Unknown  PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing
Condition: Heart Failure, Congestive
Intervention: Device: BioZ Dx
Outcome Measures: Time in days to first heart failure hospitalization following study enrollment compared between study arms;   Time in days to the first heart failure hospitalization or all-cause death between study arms (a composite endpoint without weighting);   Number of total heart failure hospitalizations compared between study arms;   Improvement in Quality of Life scores compared between study arms at 4, 12, 24, and 52 weeks versus baseline;   Improvement in Patient Global Assessment compared between study arms at 4, 12, 24, and 52 weeks versus baseline;   NYHA functional class at 4, 12, 24, and 52 weeks versus baseline in the ICG study arm;   Prognostic capability of the blinded BioZ score in the Standard Care arm for short-term heart failure events.
13 Recruiting Effectiveness of a Website and Telemonitoring in Patients With Heart Failure.
Condition: Heart Failure
Interventions: Other: Educational website (in addition to usual care).;   Other: Website and interactive platform with telemonitoring.
Outcome Measures: Change in self-care behaviour measured with the validated European Heart Failure Self Care Behaviour Scale(EHFScB scale);   Change in health related quality of life measured with the generic short-form health survey with 36 questions (SF36), EuroQol five Dimensions (EQ-5D) and the disease-specific Minnesota Living with Heart Failure Questionnaire (MLHFQ);   Number of patients who died of all causes;   Number of heart failure related hospitalisations;   Duration of heart failure related hospitalisations;   Change in disease specific knowledge measured with the Dutch Heart Failure knowledge scale.;   Change in heart function measured with blood values.;   Change in use of website.;   Cost-effectiveness
14 Unknown  Remote Monitoring of Chronic Heart Failure in Veneto Region
Condition: Congestive Heart Failure
Intervention: Procedure: Telemonitoring for patients with Congestive Heart Failure
Outcome Measures: Combined end point of all cause mortality and number of hospitalisations for heart failure;   Cardiovascular and all-cause mortality;   Health-Related Quality of Life;   Number of hospitalisations (including rehospitalisations) for all causes and for heart failure;   Total number of days in hospital;   Number of specialist visits;   Number of visits at emergency department for heart failure;   Anxiety and depression status
15 Recruiting Role of USCOM in Adult Patients With Heart Failure
Conditions: Acute Decompensated Heart Failure;   Congestive Heart Failure Compensated
Interventions: Device: Ultrasonic cardiac output monitor;   Device: Echocardiography
Outcome Measures: Difference in mean (SD) inotropy between New York Heart Association (NYHA) stages I, II, III and IV;   Difference in mean (SD) vti, FTc, SV, SVI, CO, CI, MD, SVR, SVRI, SVV, DO2, DO2I, Inotropy and ejection fraction;   Difference in mean (SD) vti, FTc, SV, SVI, CO, CI, MD, SVR, SVRI, SVV, DO2, DO2I, Inotropy and AHA stage;   Agreement between CO and SV measured separately by USCOM and 2D-Echo;   Number of subjects with and without Major Adverse Cardiac Events (MACE).;   Number of subjects with and without acute decompensated heart failure syndrome (adHFS)
16 Not yet recruiting Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
Conditions: Chronic Heart Failure;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV
Interventions: Other: Early homebased rehabilitation after hospital admission;   Other: Usual care
Outcome Measures: Readmission due to heart failure;   Physical capacity;   Activity of Daily Living;   Number of total hospital admissions;   Exercise Compliance;   Anxiety and depression;   Quality of life;   Number of patients who starts outpatient cardiac rehabilitation after intervention (municipality or hospital)
17 Recruiting EVIdence Based TreAtment - Heart Failure (EVITA-HF)
Condition: Heart Failure
Intervention:
Outcome Measures: Characteristics of consecutive patients with chronic cardiac insufficiency and an EF ≤ 40% in hospital daily routine within Germany;   Specification of the medical therapy according to the guidelines;   Monitoring of innovations of new therapy possibilities once these are introduced on the market;   Specifications of implantable devices including ICD and CRT as well as the procedure of implantation and the success of the surgical intervention;   Further interventions during clinical stay, after the index-event;   Hospital mortality and non-fatal complications;   Mortality and non-fatal complications within the first year;   Symptomatic and frequency of rehospitalisation;   Medicinal and non-medicinal therapy after 12 months;   Association between iron therapy and prognosis in patients with heart failure
18 Recruiting Management of Patients With HF by Using Educational or Educational & Telephone or Telephone Interventions and Support in Cyprus
Condition: Heart Failure
Interventions: Other: In person education on heart failure topics before discharge;   Other: Telephone support and education post-discharge;   Other: Pre-discharge in person education and post-discharge telephone education and support
Outcome Measures: Change from baseline in heart failure related quality of life at 3 months;   Change from baseline in heart failure self-care behavior at 3 months;   Combined outcome of readmission or death at 3 months post discharge;   Change in heart failure knowledge from baseline to 3 months;   Change from baseline in general health status (functioning) at 3 months
19 Recruiting China National Heart Failure Registry
Conditions: Cardiac Failure;   Congestive Heart Failure
Intervention: Other: No interventions
Outcome Measures: Number of death;   Number of patients rehospitalized for worsened heart failure
20 Recruiting Studies Investigating Co-morbidities Aggravating Heart Failure
Conditions: Heart Failure;   Type 2 Diabetes Mellitus
Intervention:
Outcome Measures: Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.;   Change in exercise capacity and cardiorespiratory reflex control;   Change of body composition and its changes over time;   Incidence and prevalence of sleep-disordered breathing and its impact on the clinical severity in patients with chronic heart failure;   Impact of impaired vascular reactivity on impaired skeletal muscle metabolic and functional capacity, including its underlying mechanisms;   Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexia

These studies may lead to new treatments and are adding insight into Morphine Sulfate Cr Tablet 10 Mg etiology and treatment.

A major focus of Morphine Sulfate Cr Tablet 10 Mg research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Morphine Sulfate Cr Tablet 10 Mg